First human test of new depression pill checks safety
NCT ID NCT04981561
Summary
This early-stage study aimed to check the safety and side effects of a new oral drug called AGN-241751 (zelquistinel), which is being developed for major depressive disorder. It involved 68 healthy volunteers who received a single dose of the drug or a placebo. The main goal was to see how well the drug was tolerated and to measure how the body absorbs and processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.